Abstract:Effective, non-addictive therapeutics for chronic pain remain a critical need. While there are several potential therapeutics that stimulate anti-inflammatory mechanisms to restore homeostasis in the spinal dorsal horn microenvironment, the effectiveness of drugs for neuropathic pain are still inadequate. The convergence of increasing knowledge about the multi-factorial mechanisms underlying neuropathic pain and the mechanisms of drug action from preclinical studies are providing the ability to create pharmaceuticals with better clinical effectiveness. By targeting and activating the peroxisome proliferator-activated receptor gamma subunit (PPARγ), numerous preclinical studies report pleiotropic effects of thiazolidinediones (TDZ) beyond their intended use of increasing insulin, including their anti-inflammatory, renal, cardioprotective, and oncopreventative effects. Several studies find TDZs reduce pain-related behavioral symptoms, including ongoing secondary hypersensitivity driven by central sensitization. Previous studies find increased PPARγ in the spinal cord and brain regions innervated by incoming afferent nerve endings after the induction of neuropathic pain models. PPARγ agonist treatment provides an effective reduction in pain-related behaviors, including anxiety. Data further suggest that improved brain mitochondrial bioenergetics after PPARγ agonist treatment is a key mechanism for reducing hypersensitivity. This review emphasizes two points relevant for the development of better chronic pain therapies. First, employing neuropathic pain models with chronic duration is critical since they can encompass the continuum of molecular and brain circuitry alterations arising over time when pain persists, providing greater relevance to clinical pain syndromes. Assisting in that effort are preclinical models of chronic trigeminal pain syndromes. Secondly, considering the access to nerve and brain neurons and glia across the blood-brain barrier is important. While many therapies have low brain penetrance, a PPARγ agonist with better brain penetrance, ELB00824, has been developed. Purposeful design and recent comparative testing indicate that ELB00824 is extraordinarily efficient and efficacious. ELB00824 provides greatly improved attenuation of pain-related behaviors, including mechanical hypersensitivity, anxiety, and depression in our chronic trigeminal nerve injury models. Physiochemical properties allowing significant brain access and toxicity testing are discussed.

Therapeutic potential of luteolin-loaded poly(lactic-co-glycolic acid)/modified magnesium hydroxide microsphere in functional thermosensitive hydrogel for treating neuropathic pain

Mesoporous Silica Particles As a Multifunctional Delivery System for Pain Relief in Experimental Neuropathy.

In situ delivery of a curcumin-loaded dynamic hydrogel for the treatment of chronic peripheral neuropathy

Achieving Long-Acting Local Analgesia Using an Intelligent Hydrogel Encapsulated with Drug and Ph Regulator.

A sustained-release gel alleviates neuropathic pain in SNI mice by reversing Glu/GABA imbalance and chloride efflux disorders

Thermo-Responsive PLGA-PEG-PLGA Hydrogels As Novel Injectable Platforms for Neuroprotective Combined Therapies in the Treatment of Retinal Degenerative Diseases

Analgesic and potentiated photothermal therapy with ropivacaine-loaded hydrogels

Injectable, Antioxidative, And Neurotrophic Factor-Deliverable Hydrogel For Peripheral Nerve Regeneration And Neuropathic Pain Relief

Protein-Functionalized PLGA Nanoparticles of Lamotrigine for Neuropathic Pain Management

Effect of Bufalin-PLGA Microspheres in the Alleviation of Neuropathic Pain Via the CCI Model.

A PLGA-PEG-PLGA Thermosensitive Gel Enabling Sustained Delivery of Ropivacaine Hydrochloride for Postoperative Pain Relief.

Effects of intrathecal and intracerebroventricular administration of luteolin in a rat neuropathic pain model

Building and Testing PPARγ Therapeutic ELB00824 with an Improved Therapeutic Window for Neuropathic Pain

Soluble Hyaluronic Acid Microneedle Arrays Mediated RGD-modified Liposome Delivery for Pain Relief During Photodynamic Therapy by Blocking TRPV1

Anti-Allodynic Effects of Polydeoxyribonucleotide in an Animal Model of Neuropathic Pain and Complex Regional Pain Syndrome

Paravertebrally-Injected Multifunctional Hydrogel for Sustained Anti-Inflammation and Pain Relief in Lumbar Disc Herniation

Amitriptyline nanoparticle repositioning prolongs the anti-allodynic effect of enhanced microglia targeting

Analgesic Microneedle Patch For Neuropathic Pain Therapy

IKBKB siRNA-Encapsulated Poly (Lactic- co-Glycolic Acid) Nanoparticles Diminish Neuropathic Pain by Inhibiting Microglial Activation

Preparation and Evaluation of PLGA-Coated Capsaicin Magnetic Nanoparticles

Toward a solid microneedle patch for rapid and enhanced local analgesic action